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Herbal Products
Cigdem Kahraman, Zekiye Ceren Arituluk  
and Iffet Irem Tatli Cankaya
Abstract
Approximately 70% of the world’s population has been using medicinal herbs as a 
complementary or alternative medicine that has grown tremendously in both developed 
and developing countries over the past 20 years (World Health Organization Drugs 
Strategy 2002–2005). This increase in consumer demand for medicinal plants contin-
ues, although scientific data are rare to create safety and efficacy profiles. Its popularity 
is also related to easy availability, cost-effectiveness leading to better purchasing power, 
and various factors that perceive that they are generally safe. Herbs are often admin-
istered simultaneously with therapeutic drugs for the treatment of major ailments, 
and herb-drug interactions (HDIs) increase their potential. The main routes proposed 
for HDIs include cytochrome P450 (CYP450)-mediated inhibition or induction and 
transport and flow proteins. In our review, we highlighted herbal medicines used for the 
treatment of various diseases with pharmacokinetic, pharmacodynamic analysis and 
case reports together with their adverse effects and herb-drug interactions. Therefore, 
this review can be used as a quick reference database for physicians and healthcare 
professionals involved in therapy, aiming to maximize clinical outcomes by reducing the 
negative and toxic effects of plants along with avoiding herb-drug interactions.
Keywords: herbs/plants, herbal products, natural products, drugs, interactions, 
toxicity
1. Introduction
Herbal products are considered the best choice as complementary medicine 
in western countries, especially in the United States and Europe. Annual sales of 
dietary herbal supplements in the United States increase 6.8% year over year. In 
addition, China and India are the top export countries, while Hong Kong, Japan, 
the United States, and Germany are the leading importers. The Confederation of 
Indian Industry (CII) presented that the market size of the Ayurvedic industry in 
the country is $ 4.4 billion, and the total market size of the Indian health industry is 
$ 11.8 billion. There has been an increase in demand for “complementary” medi-
cines, including those of plant origin. In addition, there is a significant increase in 
the self-administration of herbal medicines among the public. In the context of the 
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growing demand and use of herbal medicines for patients and the public, and  
the subsequent interests of the regulatory authorities, comprehensive research 
on the safety and effectiveness of herbal products, including the possibility of 
interactions when simultaneous application is required, should be encouraged. This 
is because all herbal medicines and dietary supplements are a complex mixture con-
taining multiple active phyto-components that increase the possibility of herb-drug 
interaction (HDI). Most people who consume herbal products and supplements 
do not show this to their pharmacist or doctor, thereby increasing the likelihood 
of HDI being identified and resolved over time. However, data from recent studies 
show that there is potential for serious interaction between some commonly used 
herbs/herbal products and commonly used standard medications [1].
In our review, we highlighted herbal medicines used for the treatment of 
various diseases with their adverse effects and herb-drug interactions, and stated 
recommendations for proper use of plants that might prevent possible risks for 
future incidents.
2. Toxicological risks of plants and herbal products
General risks associated with herbs and/or herbal products include:
• Misidentification without assigning with Latin names. Possible causes of 
misidentification include contamination of cultivated plants with weeds, and 
resembling plants mistaken for herbs collected in the wild.
• Contamination with harmful substances such as heavy metals, polycyclic 
aromatic hydrocarbons, dioxins, as well as natural toxins or microorganisms.
• Interaction with other drugs, such as antagonism or synergism, and medical 
tests that potentially lead to misdiagnosis.
• Adulteration with other medicinal drugs.
• Intrinsic toxicity caused by the presence of natural toxins, such as aristolochic 
acids [2].
2.1 Nephrotoxicity
The drug or toxin that causes kidney damage when exposed to a certain level 
cannot pass the excess urine, and the waste product is what is called nephrotoxicity. 
In this case, there is an increase in blood electrolytes, such as potassium and magne-
sium. This situation begins temporarily but can be serious if it is not detected before. 
Blood urea nitrogen (BUN) test and creatinine levels in the blood are two simple 
tests called as kidney function tests used to detect the nephrotoxicity. For healthy 
individuals, the normal levels of BUN and creatinine are between 10–25 mg/dl and 
0.7–1.4 mg/dl, respectively. The following factors may increase these values:
a. Dehydration.
b. Obstruction of blood flow to or from kidney caused by a tumor, stone, or 
irregular heart rhythms.
c. Nephritis or urinary tract infection.
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d. The aftermath of diseases such as diabetic neuropathy, congestive heart failure, 
and enlarged prostate gland in man.
e. Gastrointestinal bleeding.
f. Prolonged hypotension.
g. Protein-rich diets.
h. Radiocontrast dye injected intravenously to improve visibility.
i. Drug toxicity with some chemotherapeutics (carboplatin, carmustine, cispl-
atin, methotrexate, and mitomycin) and biological therapeutic agents (inter-
leukin-2 and interferon-alpha), antibiotics (amphotericin B, gentamicin, and 
vancomycin), NSAIDs (ibuprofen), diuretics (furosemide), and ACE inhibi-
tors (captopril, benazepril, and enalapril).
j. Nephrotoxicity after taking herbal medicine.
The cause of nephrotoxicity after taking herbal medicine may be the addition of 
toxins during careless preparation, addition of adulterants, heavy metals, and some 
pharmaceutical products intentionally reducing costs or increasing effectiveness [3].
About 50 plants were related to kidney damage case reports published in 
PubMed in the last 50+ years (from 1966 to May 2016). Herbs include Aristolochia 
fangchi Y.C.Wu ex L.D.Chow & S.M.Hwang, Artemisia herba-alba Asso, Callilepis 
laureola DC., Cupressus funebris Endl., Ephedra sinica Stapf, Hypericum perforatum 
L., Taxus celebica (Warb.) H.L.Li, Tribulus terrestris L., and Tripterygium wilfordii 
Hook.f. Aristolochia species containing aristolochic acid, Aristolochia fangchi, had the 
highest number of publications (not actual cases) [4].
2.2 Hepatotoxicity
Hepatotoxicity (“Hepar” means liver and “Toxicon” means poison in ancient 
Greek) implies liver damage caused by medication, chemical, herbal, or dietary 
supplements. Stomach pain, vomiting, nausea, chance in urine and stool color, rash, 
jaundice, frequent tiredness, weakness, fatigue, and fever are the main symptoms 
of the damage. Some liver function tests performed on blood samples allow detect-
ing hepatotoxicity in the laboratory. These tests include alanine transaminase test 
(normal range 7–55 U/l), alkaline phosphatase test (normal range 45–115 U/l), 
albumin test (normal range 3.5–5.0 g/dl), aspartate transaminase test (normal range 
8–48 U/l), and bilirubin test (normal range 0.1–1.2 mg/dl). Increased ALT, ALP, 
AST, and bilirubin and decreased albumin levels demonstrate hepatotoxicity. The 
levels of ALP also increase during pregnancy [3].
The causes of liver damage are both hepatocellular and extracellular mechanisms 
such as hepatocyte disruption, transport protein disruption, T-cell activation, 
hepatocyte apoptosis, disruption of mitochondria, injury of bile duct, drug toxicity, 
and drug interaction [3].
Drug toxicity mechanisms: drugs are the main cause of hepatotoxicity. About 
900 drugs, toxins, and herbs have been reported for hepatotoxicity. There are two 
types of drug reactions: the first is the reaction that directly affects the liver, called 
internal drug reactions; and the other is the reaction that mediates the immune 
response, called idiosyncratic drug reactions. In the first category, the drug itself or 
its metabolite produces a dose-dependent injury, such as paracetamol and carbon 
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tetrachloride. In the second category, hypersensitivity reactions, for example, phe-
nytoin reaction, cause an immunoallergic or metabolic idiosyncratic reaction due 
to fever, rash, eosinophilia and indirect drug reaction for a short time. The second 
reaction type response rate is variable, for example, halothane [3].
Drug interaction mechanisms: when some drugs are taken at the same time, they 
react together and cause liver damage. For example, the combination of tylenol with 
INH, histamine, laniazide, and nydrazide can be hepatotoxic [3].
When hepatotoxicity caused by herbal drug intake is discussed, case rates are often 
reported. The severity of toxicity varies greatly between mild hepatitis and acute liver 
failure. The scoring system for allopathic drugs can be evaluated, but not suitable for 
herbal medicines and needs validation. Many Ayurvedic and Chinese herbal medi-
cines are reported to cause hepatotoxicity. The main hepatotoxic herbs are Cimicifuga 
racemosa (L.) Nutt., Larrea tridentata (Sessé & Moc. ex DC.) Coville, Scutellaria 
baicalensis Georgi, Scutellaria lateriflora L., Teucrium chamaedrys L., etc. [3].
2.3 Cardiotoxicity
Cardiotoxicity is a term used for damage to the heart or change heart functions. 
It is a condition where there is a change in the electrophysiological function of the 
heart or damage to the heart muscle, weakening the heart and causing poor blood 
circulation. This can be detected by symptoms such as dry, unproductive cough; 
inflammation in the ankles, hands, feet, and neck vessels; irregular heartbeat; 
tachycardia; cardiomegaly; weakness; dizziness; etc. [3].
Herbal drugs that have a direct effect on the heart include medicine prepared 
from plants such as Aconitum napellus L., Atropa belladonna L., Catharanthus roseus 
(L.) G.Don, Digitalis purpurea L., Ephedra distachya L., Glycyrrhiza glabra L., 
Mandragora officinarum L., etc. [3].
2.3.1 Potential precautions of plants on hypertension
Herbal products are widely used in the general population and many are encour-
aged for the natural treatment of hypertension. Patients with hypertension often 
prefer to use these products in addition to or instead of pharmacological antihy-
pertensive agents. Due to the frequent use of herbal products, both consumers and 
healthcare providers should be aware of the major issues surrounding these prod-
ucts and factors affecting both effectiveness and damages (Table 1) [5].
Herbal/natural 
products for 
evidence of benefit
Herbs/herbal products for 
evidence of harm
Causes
Coenzyme Q10 Ephedra spec. (Ephedra) Cardiac effects, hypertension, 
palpitations, tachycardia, stroke, 
seizures
Fish oil Citrus × aurantium L. (Bitter orange) Blood pressure increases occur in 
healthy people
Allium sativum L. 
(Garlic)
Eleutherococcus senticosus (Rupr. & 
Maxim.) Maxim. (Siberian Ginseng)
Hypertension, tachycardia, 
palpitations
Vitamin C Glycyhrriza glabra (Licorice) Mineralocorticoid excess syndrome, 
subsequent hypertension
Table 1. 
Herbal/natural products in hypertension for their benefits and disadvantages.
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2.4 Neurotoxicity
The physical brain damage occurred by exposure to neurotoxin is stated as neuro-
toxicity. Neurotoxin is a substance that causes changes in the nervous system activity 
by disrupting or killing neurons. Neurotoxicity symptoms are generally emotional 
disorders, visual impairment, extremity failing, sexual dysfunction, headache, and 
behavioral alteration. Atropa belladonna, Brugmansia species, Catharanthus roseus, 
Cannabis sativa L., Conium maculatum L., Coscinium fenestratum (Goetgh.) Colebr., 
Datura stramonium L., Hyoscyamus niger L., and Papaver somniferum L. are the com-
mon medicinal herbs that have potential neurotoxic effects [3].
2.4.1 Psychiatric and neurological adverse effects
Psychiatric and neurological patients often try herbal medicines assuming they 
are safe. Numerous case reports include various adverse events such as cerebral 
arteritis, cerebral edema, delirium, coma, confusion, encephalopathy, hallucina-
tions, intracerebral hemorrhage and other cerebrovascular accidents, movement 
disorders, mood disorders, muscle weakness, paresthesia, and seizures. Some 
deaths have been recorded. Misuse is caused by toxicity of herbal ingredients, 
contamination and adulteration, and herb-drug interactions [6] (Table 2).
Herbs Adverse effects Potential drug interactions
Panax ginseng C.A.Mey. Insomnia, vaginal bleeding, mastalgia, 
mania
Phenelzine, hypoglycemic drugs
Valeriana officinalis L. 
(Valerian)
Headache, GI symptoms, hangover Other CNS depressants
Datura stramonium 
(Jimson weed)*
Ataxia, blurred vision, disorientation, 
other cholinergic signs
Other anti-cholinergic agents
Glycyrrhiza glabra 
(Licorice)
Mineral corticoid effects Antihypertensives, 
corticosteroids, digoxin
Passiflora incarnata L. 
(Passionflower)
Nausea, drowsiness, ventricular 
tachycardia
Other CNS depressants
Mentha pulegium L. 
(Pennyroyale)
GI symptoms and cramps, confusion, 
hallucination, liver failure
Inhibitors of cytochrome P-450 
system
Piper methysticum G.Forst. 
(Kava)*
GI symptoms, restlessness, allergies, 
hepatitis
Other CNS depressants
Ephedra sinica (Ma 
Huang)*
Anxiety, confusion, insomnia, 
psychosis
Other CNS-stimulants, 
beta-blockers, MAO-inhibitors, 
phenothiazines, theophylline
Ginkgo biloba L. GI symptoms, allergies, headache, 
dizziness, bleeding
Anticoagulants
Tripterygium wilfordii 
(Thunder God Vine)*
Dryness of mouth, nausea, GI 
symptoms, leukopenia
Not known
Eucalyptus sp. Cyanosis, delirium, GI symptoms Not known
Hypericum perforatum (St. 
John’s wort)
GI symptoms, allergies, fatigue, anxiety Serotonin reuptake inhibitors, 
hepatic enzyme inducer
Aconitum sp. (Aconite)* Acidosis, bradycardia, diarrhea, 
hypokalemia
Antiarrhythmics, 
antihypertensives
*Although we know the unconscious use of plants or their products, some of the plants given in the table are potent 
plants that are undesirable to be used in phytotherapy, but they are generally used in Traditional Chinese Medicine.
Table 2. 
Herbal remedies implicated in causing neurological adverse effects [6].
Medical Toxicology
6
2.5 Skin toxicity
Cutaneous toxicity is a term used for a pronounced negative effect such as skin 
irritation, inflammation, or rashes of the epidermal growth factor receptor caused 
by exposure to a plant, chemical, or environmental factor. Skin consisting of a layer 
of dead cells and several layers of living cells is the largest organ and a defensive 
barrier of the body. When irritant influences into the skin, the living cells react due 
to cause inflammation or dermatitis. Inflammation consists of four parts including 
redness, pain, heat, and swelling. Skin toxicity can be detected easily as the reaction 
is observed immediately. The most common sources of skin toxicity are food and 
cosmetics, and others are medicated lotions, balms, creams, inhalers, and essential 
oils. Various herbal ingredients are available in all the cosmetics and medicinal 
products mentioned above. Types of skin sensitization reactions include:
Primary irritant dermatitis: it is a direct irritation of the skin, such as redness, 
itching, pain, blusters, peeling, or open wounds. Primary irritant dermatitis may be 
caused by plants such as, Asclepias syriaca L., Cannabis sativa, Dieffenbachia amoena 
Bull., Digitalis purpurea, Ficus carica L., Hevea brasiliensis (Willd. ex A.Juss.) Müll.
Arg., Narcissus pseudonarcissus L., Primula veris L., Ranunculus acris L., Ricinus 
communis L., Tulipa gesneriana L., etc. Common foods such as Agaricus bisporus L., 
Apium graveolens L., Brassica rapa L., Cucumis sativus L., Daucus carota L., Pastinaca 
sativa L., Petroselinum crispum (Mill.) Fuss, and Solanum lycopersicum L. can also 
cause primary irritant dermatitis.
Allergic contact dermatitis: it is a real allergic response and varies from person 
to person. Toxicodendron diversilobum (Torr. & A.Gray) Greena and Toxicodendron 
rydbergii (Small ex Rydb.) Greene, Allium cepa L., Allium sativum, Anacardium 
occidentale L., Apium graveolens, Cedrus deodara (Roxb. ex D.Don) G.Don, 
Dendranthema grandiflorum (Ramat.) Kitam., Hedera helix L., Marchantiophyta 
species, Narcissus pseudonarcissus, Primula vulgaris Huds., Pinus sabiniana Douglas, 
Toxicodendron vernix (L.) Kuntze, and Tulipa gesneriana are the most common 
plants that produce allergic contact dermatitis.
Photosensitization dermatitis: it is a cutaneous toxic response caused by exposure 
to sunlight when a photosensitizer (sunlight sensitive compound) is present in the 
body and can be detected by sunburn-like reactions in pigment-free areas. Plants 
such as Agave lechuguilla Torr., Bassia scoparia (L.) A.J.Scott, Hypericum species (St 
John’s wort), Lantana camara L., Tetradymia species, and Tribulus terrestris cause 
photosensitive dermatitis [3].
There is another type of phototoxic photosensitization caused by contact with 
some plants. Such a reaction occurs when a photoactive chemical produced by 
plants touches the skin, and is absorbed and activated by sunlight. Intensity varies 
depending on time and exposure amount. Anethum graveolens L., Apium graveolens 
L., Brassica oleracea L., Citrus aurantiifolia (Christm.) Swingle, Daucus carota, 
Ficus carica, Hypericum perforatum (St. John’s wort), Petroselinum crispum, and 
Ranunculus acris are reported to produce contact photosensitization [3].
3. Contamination of herbal medicines by tropane alkaloids
Tropane alkaloids that have been known as toxic and hallucinogenic are mainly 
seen in Solanaceae plants (Atropa belladonna, Hyoscyamus niger, Datura stramo-
nium, etc.). All over the world, anticholinergic poisoning is observed due to the 
contamination of herbal teas and plants with tropane alkaloids. Tropane alkaloid 
poisoning can occur after consumption of any medicinal plant from Solanaceae 
family as contaminants. Globally, almost all reports from 1978 to 2014 include one 
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of the herbs prescribed in herbal teas. Contamination is most likely to occur during 
harvesting or processing. For herbs, on-site inspection is required to exclude cross-
contamination at the retail level and accidental mixing. The diagnosis is confirmed 
by screening for the presence of Solanaceae species and tropane alkaloids. Since, if 
these relatively heat-resistant alkaloids contaminate the herbal teas and other herbs 
in large quantities, significant health hazards may occur, the significance of good 
agricultural and collection practices (GACPs) for medicinal plants is accentuated by 
WHO repeatedly. The DNA barcode is also increasingly used to exclude the pres-
ence of pollutant (especially toxic species) and product substitution. All suspect 
cases should be reported to health authorities so that investigations throughout the 
supply chain and early intervention measures to protect the public can be taken [7].
4. Herb-drug interactions with the plants including furanocoumarins
Naturally occurring furanocoumarins are abundant in citrus fruits, vegetables, 
and medicinal herbs from the Apiaceae, Fabaceae, and Rutaceae families. Grapefruit-
drug interactions were first discovered by chance in 1989 where 5-fold higher 
felodipine plasma concentrations were observed. Consumption of grapefruit juice 
has increased the oral bioavailability of various drugs, including calcium channel 
blockers (e.g., felodipine, nifedipine), HMG-CoA reductase inhibitors (simvastatin, 
lovastatin), benzodiazepines (midazolam, triazolam), antihistamines (terfenadines), 
and immunosuppressants (cyclosporine). In addition, phototoxicity developing with 
furanocoumarins occurs as a result of exposure to sunlight, following contact with 
the plant. Phototoxicity results in acute dermatitis, sometimes blisters, and vesicles. 
In many cases, prolonged hyperpigmentation is observed. Photochemotherapy for a 
long time with furanocoumarins can also cause cancer (skin and liver) [8].
5. Toxicity of pyrrolizidine alkaloids
Pyrrolizidine alkaloids (PAs) are common components of hundreds of plant 
species of unrelated botanical families scattered across many geographical regions 
of the world. In more than 6000 plants belonging to three large plant families, 
Asteraceae, Boraginaceae, and Fabaceae, above 660 PAs and PA N-oxides have been 
identified and about half of them are toxic. More than 10,000 cases of PAs poison-
ing have been documented worldwide, most of which resulted from exposure to 
food contaminated with PAs. Acute toxicity from PA is mainly seen in the liver, 
including hemorrhagic necrosis, hepatic megalocytosis, venous occlusion, liver 
cirrhosis, and hepatic  carcinomas, and chronic exposure to PAs, from herbs/dietary 
products containing PAs, can lead to kidneys, pancreas, gastrointestinal tract, bone 
marrow, and brain. It is a worldwide public health problem due to the high risk of 
human exposure to genotoxic and tumorigenic PAs, and the International Program 
on Chemical Safety has concluded that PAs are a threat to human health and safety. 
Regulations have been constituted to restrict its use [8].
6. Adverse effects of anthraquinone derivatives
Anthraquinone derivatives with a laxative effect appear in a number of plants: 
Sennae folium, rhei rhizoma, frangulae cortex, and aloe. They have a laxative 
effect by directly stimulating the colonic smooth muscles. The adverse effects 
of laxative anthraquinone drugs are more likely to be caused by excessive loss of 
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fluids and electrolytes, especially potassium loss, associated with the use of high 
doses. Higher doses also drain a larger portion of the colon, and the resulting 
natural absence of defecation over the next day leads to reuse of anthraquinone. 
Prolonged use of laxatives due to laxative addiction should be avoided, as it may 
have a detrimental effect on the intestinal mucosa, leading to a condition known as 
Melanosis coli. This is usually seen after at least 9–12 months of regular stimulant 
laxative use. Undesirable effects such as abdominal spasms and pain, urine color 
change by metabolites, and hemorrhoid congestion are common. A report from 
China reported that patients with senna leaf tea addiction as laxatives suffer from 
symptoms of fidgetiness, sleeplessness, dilated pupils, and loss of appetite while 
consuming 5–9 g of senna daily. Rare cases of hepatic inflammation induced 
by anthraquinone derivatives have been reported and may be dose dependent. 
Hypokalemia, which occurs as the effect of long-term use of laxative drugs, 
strengthens the effect of cardiac glycosides and interacts with antiarrhythmic 
drugs. Using other drugs (diuretics, adrenocorticosteroids, and licorice) that cause 
hypokalemia can speed up electrolyte imbalance. Contraindications for anthracene 
laxatives are intestinal obstruction and chronic intestinal inflammation such as 
stomach or duodenal ulcer or ulcerative colitis [9].
7. Adulterations
Many reports on the adulteration of herbal products with synthetic drugs have 
been systematically reviewed and published with case reports. The list of herbal 
products and adulterants produced in this way is quite impressive and caused 
serious side effects (Table 3). A case with the latest herbal product adulterated is 
related to a 56-year-old man from Indonesia. While visiting Australia, he was hos-
pitalized in a mixed condition arising from hypoglycemia. He insisted that type II 
diabetes was controlled only by diet. However, despite dextrose infusions, glucose 
levels do not normalize. It was eventually discovered that he also received a TCM 
“Zhen Qi” from Malaysia. It was analyzed and shown to contain glibenclamide. 
Like that, in some cases, patients were severely damaged. Examples of serious side 
effects include agranulocytosis, Cushing’s syndrome, coma, over-anticoagulation, 
gastrointestinal bleeding, arrhythmias, and various skin lesions. Due to the 
adulteration of herbal products with synthetic drugs, adequate and necessary 
procedures should be applied, and whole herbal products should be analyzed 
before marketing [10].
Acetaminophen Dexamethasone Glibenclamide
Aminopyrine Dexamethasone acetate Hydrochlorothiazide
Betamethasone Diazepam Hydrocortisone
Caffeine Diclofenac Indomethacin
Chlordiazepoxide Ethoxybenzamide Mefenamic acid
Chlorzoxazone Fluocinolone acetonide Methylsalicylate
Clobetasol propionate Fluocortolone Phenacetin
Corticosteroids Fluocortolone Phenylbutazone
Phenytoin Prednisolone Sibutramin
Sildenafil
Table 3. 
Adulterants found in herbal products.
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8. Heavy metal contaminations
It is possible to come across heavy metals such as cadmium, cobalt, copper, iron, 
manganese, nickel, lead, zinc, and mercury in concentrations that are not produced 
within the framework of certain rules, especially the traditional Chinese herbal 
preparations. This contamination is probably caused by contamination during 
drying and preservation. With severe complications that may occur, these types of 
products are unlikely to cause adverse health effects, even if they are not consumed 
in large quantities for long periods of time [11].
9. Herb-drug interactions (HDI)
There are no molecules in nature that have no effect. Therefore, this diversity 
increases the variety of products while increasing the probability of interaction. If the 
effect of a drug is changed qualitatively or quantitatively by another substance (herbal 
medicine/product/ingredient), there is an interaction between these two drugs. It 
can be said as a rule that two drugs should be present at the same time in the body, 
especially in the place of interaction, for interaction to occur. But sometimes, if the 
drug causes a permanent effect on the body, interaction can occur even if such a drug 
is not found in the body. Interaction is sometimes deliberately created to increase the 
therapeutic effect of one drug with another drug or to reduce its side effects, which 
are useful interactions. In other cases, the interaction may occur undesirably as a 
result of unauthorized use of medicines or when the patient is starting treatment with 
a particular medication. Sometimes, unpredictable interactions due to new drugs may 
occur. Drug-related as well as disease-related factors (patient’s age, gender, genetic 
characteristics, pathological condition), such as the posology and method of adminis-
tration, pharmacokinetic, pharmacodynamic, and therapeutic properties of the drug 
may cause interactions between medicines and herbal medicines (Figure 1) [12].
It is observed that the use of herbal medicines/herbal products is more common 
in the geriatric group aged 65 and over, and the use in women in this adult population 
is higher than in men. Herbs/herbal products/drug interaction is higher in patients 
using drugs with narrow therapeutic index. Information on herbs-herbal products/
drug/component interactions is based on in vitro tests, in vivo animal experiments, 
Figure 1. 
The important risk factors that influence the occurrence of interactions between herbal products and 
conventional drugs [13].
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and case reports. Many mechanisms play a role in these interactions, and interactions 
are seen in two main types as pharmacokinetic and pharmacodynamic interactions. 
Pharmacokinetic interactions result in changes in drug absorption, distribution, 
metabolism, and elimination. These interactions usually occur far away from the 
drug’s effect and lead to a decrease or increase in effect as a result of the change in 
drug concentration in body fluids. In order to say that there is a pharmacokinetic 
interaction, the plasma level or half-life of the drug should be determined experi-
mentally. Various interactions such as cytochrome P450, UDP-glucuronyl-transferase 
(UGTs), and carrier proteins such as P-glycoprotein (P-gp) are thought to play a role 
in these interactions. Pharmacokinetic interactions are the most common interactions 
as a cause of undesirable side effects. If the herb or natural products or its second-
ary metabolites inhibit an enzyme involved in drug metabolism, it may increase the 
potential for toxic effects, as it will reduce the metabolism of drugs that metabolize 
the enzyme and turn into an inactive metabolite as a result of metabolism. If the 
herbal drug induces an enzyme, a decrease in drug effect may be observed, since the 
metabolism of the drugs that are metabolized by this enzyme and converted into inac-
tive metabolite as a result of metabolism will increase. Likewise, if the drug turns into 
an active metabolite as a result of metabolism, if the herbal drug induces the enzyme 
responsible for the metabolism of the drug, an increase in drug effect or toxic effect 
may be observed as a result of increased effective metabolite concentration [12].
Pharmacodynamic interactions occur when one drug changes the effect of another, 
that is, an effect opposite or in the same direction, chemically combined with it. That 
is, if the herbal medicine and drug affect the same receptor or the same site, interaction 
occurs and a synergic or antagonistic effect may occur. While the effect of the drug 
increases as a result of the additive effect, the effect of the drug decreases or disappears 
as a result of the antagonistic effect. The concentration of the drug in body fluids, 
plasma, is not changed by the second drug. Although most of the drug metabolism is 
carried out in the liver with cytochrome P450 enzymes, the metabolism of some drugs 
can be in the blood, kidney, skin, and intestine. Approximately 50 different cyto-
chrome P450 enzymes have been identified. However, a small portion of these enzymes 
play a role in drug metabolism. Herbal drug-drug interactions are generally pharmaco-
kinetic-type interactions that result from enzyme inhibition or induction [12].
The following are the evaluation parameters used to determine the probability 
of herb-drug interactions:
a. Adequate patient history.
b. Concurrent diseases, conditions, or other drugs associated with adverse events.
c. Concomitant medications are documented.
d. The description of the interactors is sufficient.
e. Clearly, alternative explanations are excluded.
f. Chronology is complete.
g. The time sequence of drug administration to adverse event is reasonable.
h. An adverse event has been sufficiently defined.
i. The event ends after stopping the medicine.
j. The activity repeats upon challenge again [3].
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9.1.  Herb-drug interactions in the treatment of cardiovascular  
disorders (CVDs)
In 2015, an estimated 422.7 million cases of cardiovascular disease (CVD) and 
17.92 million CVD deaths were reported worldwide. And most people in the world 
still prefer complementary and alternative medicine (CAM) as their first treat-
ment option. The consumption of over-the-counter CAM consumption increases 
the risk of HDI, which endangers the effective medical management of CVD. In 
cardiac therapy, the narrow therapeutic drug window and a wide range of cardiac 
drugs available for treatment are also a major cause of concern for HDI. People with 
chronic diseases often use CAM therapies inappropriately to manage their condition 
and thereby increase the potential or possibility of HDI formation [1].
This section of our review focuses on plants reported in the literature by preclini-
cal or clinical studies (rats or humans) or cardiovascular drugs with appropriate case 
reports. These herbs are reported to affect the pharmacokinetics of some cardiovas-
cular drugs through a variety of HDI mechanisms. Reported HDI studies of some 
plants commonly used for the treatment of CVDs are summarized in Table 4 [1].
Herbs Interacting drugs CYP, P-gp induction/inhibition
Piper longum L. Verapamil, digoxin, 
propranolol
CYP3A4, CYP2D6 and CYP1A2 (inhibition)
Curcuma longa L. Losartan, rosuvastatin, 
warfarin, clopidogrel
CYP3A4, CYP1A2, CYP2B6, CYP2C19, CYP2C9 
(inhibition)
Talinolol P-gp induction, intestinal P-gp in subjects with 
ABCB1 C3435T genotype inhibition
Fucus vesiculosus L. Amiodarone, valsartan CYP1A (induction), CYP2C9 (inhibition)
Zingiber officinale Roscoe Nifedipine, 
phenprocoumon
CYP2C9 (potent inhibition) CYP2C19, CYP3A4 
(moderate inhibition)
Terminalia bellirica 
(Gaertn.) Roxb.
Diltiazem CYP3A4 CYP2D6
Salvia miltiorrhiza Bunge Warfarin CYP3A4 (induction) CYP1A2, CYP2C9, 
CYP1E1, CYP2C6, CYP2C11 (inhibition)
Allium sativum Atorvastatin, cilostazol CYP2C9, CYP3A4 and CYP2D6 (inhibition) 
P-gp induction
Ginkgo biloba Diltiazem, cilostazol CYP1A2, CYP3A, and CYP2C9 (P-gp inhibition 
inhibition) CYP2C19 (induction)
Nifedipine Unknown
Talinolol Intestinal P-gp inhibition
Glycrrhiza glabra Atorvastatin, 
simvastatin, lovastatin
CYP2B6, CYP2C9, CYP2C19 (inhibition) 
CYP3A4 (induction)
Panax ginseng Warfarin CYP3A4 (induction), CYP2C11 (inhibition)
Nifedipine CYP3A4 (inhibition)
Pueraria montana (Lour.) 
Merr. var. lobata (Willd.) 
Sanjappa & Pradeep
Warfarin CYP 1A2 (induction) CYP2D6, CYP3A4, and 
OATs (inhibition)
Citrus paradisi Macfad. Felodipine CYP3A4 (inhibition)
Talinolol OATP inhibition
Aliskiren OATP2B1 inhibition
Atorvastatin Intestinal CYP3A4 inhibition
Lovastatin Intestinal CYP3A4 inhibition
Simvastatin Intestinal CYP3A4 inhibition
Medical Toxicology
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9.2 Herb-drug interactions with chemotherapeutic drugs
One of the most important risks associated with the combined use of herbal 
products and chemotherapeutic agents is herb-drug interactions. Patients with 
chronic illnesses who use more than one drug have a higher risk. Herb-drug 
interaction is undesirable in the treatment of cancer due to the perpendicular 
dose-effect relationship and toxicity of chemotherapeutic agents. The most 
common mechanism of herb-drug interaction is herbal mediated inhibition 
and/or stimulation of drug-metabolizing enzymes and/or transport proteins 
that lead to changes in the pharmacokinetic order of the victim drug. This focus 
on clinically significant herb-drug interaction should attract public attention, 
including practitioners, researchers, and cancer chemotherapy consumers 
(Table 5) [14].
9.3  Herb-drug interactions with attention-deficit/hyperactivity disorder 
(ADHD) medication
In some pediatric patients with attention deficit/hyperactivity disorder 
(ADHD), natural products such as herbal medicines are used. Although herbal 
remedies are thought to be safe when used appropriately, they may contain active 
ingredients that can interact with concurrently used medications and can lead to 
adverse events for natural products-drug interactions (Table 6) [15].
Herbs Interacting drugs CYP, P-gp induction/inhibition
Mentha × piperita L. Felodipine CYP3A4 (inhibition)
Hypericum perforatum Nifedipine CYP3A4 (induction)
Verapamil
Digoxin P-gp induction
Talinolol P-gp induction
Phenprocoumon CYP2C9 induction, CYY3A4 induction
Atorvastatin CYP3A4 induction, P-gp induction
Pravastatin Intestinal CYP3A4 inhibition
Simvastatin CYP3A4 induction, P-gp induction
Rosuvastatin P-gp induction
Camellia sinensis (L.) 
Kuntze.
Digoxin P-gp induction, digoxin uptake inhibition
Nadolol Intestinal OATP1A2 inhibition
Rosuvastatin Intestinal OATP1A2/OATB2P inhibition
Malus pumila Mill. Atenolol Unknown (possible mediated by OATP 
function and modulation of intestinal drug 
uptake)
Aliskiren OATP2B1 inhibition
Schisandra chinensis 
(Turcz.) Baill.
Talinolol P-gp inhibition
Citrus × sinensis (L.) 
Osbeck
Aliskiren OATP2B1 inhibition
Silybum marianum (L.) 
Gaertn.
Losartan CYP2C9 inhibition
Table 4. 
Reported HDI studies of some commonly used herbs for the treatment of CVDs [1, 13].
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9.4  Herb-drug interactions (HDI) with chronic kidney disease (CKD) 
medication
Chronic kidney disease (CKD) is defined as abnormalities in kidney structure 
or function that have been going on for more than 3 months, with adverse health 
consequences. The prevalence of CKD is estimated to be 8–16% worldwide.  
Herbs Cancer 
drugs
Study type Results
Echinacea Etoposide Case report It was found that taking echinacea 
with etoposide rarely reduced platelet 
(16 × 103/L) compared to etoposide 
alone (44 × 103/L)
Docetaxel Prospective study in 10 
cancer patients
Echinacea did not cause a significant 
change in the pharmacokinetics of 
docetaxel
Garlic Docetaxel Prospective, 
patient controlled, 
pharmacokinetic
Garlic was found to reduce docetaxel 
clearance. Although this reduction 
is not statistically significant, it can 
potentially increase side effects due to 
docetaxel accumulation
Ginseng Imatinib Case report After receiving ginseng in patients 
receiving imatinib for 7 years, 
hepatotoxicity symptoms began to 
appear. Hepatotoxicity improved upon 
discontinuation of ginseng
Grapefruit juice Docetaxel Case report Grapefruit juice has been found to  
reduce the clearance of docetaxel, 
while increasing the AUC and terminal 
half-life of docetaxel
Nilotinib Open label, randomized, 
2 period crossover
It was found that grapefruit juice 
increased the AUC and the peak 
concentration of nilotinib, but did not 
affect the elimination half-life
Milk thistle Irinotecan Pharmacokinetic study It has been found that milk thistle 
causes a statistically insignificant 
decrease in irinotecan clearance, which 
is unlikely to cause a clinical effect
St John’s wort Docetaxel Pharmacokinetic study St John’s wort was found to cause 
a significant decrease in plasma 
docetaxel concentration
Irinotecan Unblinded, randomized 
crossover study
St John’s wort caused a 42% reduction 
in plasma concentrations of the active 
metabolite (SN-38)
Imatinib Open-label, crossover 
pharmacokinetic study
St John’s wort reduced the plasma 
concentration of imatinib by 32% and 
reduced the half-life of imatinib by 21%
2-period, open-label, 
fixed sequence study
St John’s wort increased the imatinib 
clearance by 43% and decreased the 
plasma concentration by 30%
Table 5. 
Herbal interaction studies with chemotherapeutic agents conducted in human subjects [14].
Medical Toxicology
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Most importantly, patients with CKD are advised to avoid over-the-counter products 
and herbal medicines according to the Kidney Disease Improving Global Outcome 
(KDIGO) guidelines. However, several studies have revealed that many patients with 
CKD have returned to complementary and alternative medicine (CAM) for a desper-
ate treatment. The consumption of unregistered herbal products is more common 
today because these products can be easily purchased from on-line media, street mar-
kets, or stores. It is an alarming trend as it may be linked to an increase in the number 
of patients with liver and kidney failure in public hospitals. In addition, patients 
with CKD are at higher risk of developing cardiovascular disease. Most of them are 
prescribed with antiplatelet and anticoagulants. Anti-platelets and anticoagulants 
Herbs Drugs Case
Ginkgo 
biloba
Strattera An 8-year-old male patient with a history of ADHD, astigmatism, 
behavioral disorder, learning disorder, and asthma was using 25 mg 
Strattera for ADHD from October 2008 to September 2009. From May 2001 
to November 2010, he was taking 85 mg of G. biloba daily. After starting 
Strattera, the patient experienced headaches and eye pain resulting in 
hospitalization. On ophthalmological examination, suspicion of glaucoma 
appeared. The reporting child psychiatrist stated that the incident was 
related to Strattera
Efalex 
evening 
primrose oil
Ritalin A 7-year-old female was treated with Ritalin 10 mg/day orally for ADHD 
from October 2001. The patient has also been taking Efalex evening primrose 
oil since 2001. On March 7, 2002, she developed a tic including her both 
arms. It has become more complex. Ritalin was discontinued on March 7, 
2002. There was an improvement in head, arm, neck, and leg movements 
after cessation, but movements were still present. There was no history of 
tic or movement disorders in the family. Before the tics, the patient had a 
nightmare for 1 week. She also had a skin rash and dry skin in her mouth. 
The case was considered medically significant
Evening 
primrose oil
Concerta An 11-year-old male was using 36 mg of methylphenidate per day for ADHD 
for several years. The patient was also taking evening primrose oil for an 
unknown indication and duration. There was a history of moderate to severe 
developmental delay and slow learning. Methylphenidate was exhausted on 
December 30, 2002 and was brought to emergency with severe torticollis, 
rolling arm movements, lip chewing, and pharyngitis. On January 2, 2003, he 
presented to the pediatrician with the same symptoms and speech disorder, 
did not eat or drink, and was hospitalized. Torticollis improved with 
intravenous cetirizine hydrochloride. The patient was also diagnosed with 
pharyngeal abscess
St John’s 
wort
Concerta A 17-year-old female with a history of ADHD and depression was treated with 
methylphenidate for about a year. Concurrent medication included St. John’s 
wort. The patient experienced psychotic symptoms on an unknown day. The 
patient saw and heard things that were not there and disturbed at night. The 
result was considered medically significant
Ritalin A 15-year-old male started 20 mg oral/day Ritalin for ADHD in 1998 and 
tolerated it well. He suffered a period of sadness from June 1, 2001, and he 
took St. John’s wort (five drops) orally to treat his depression. A few hours 
later he presented agitation, unexplained crying, depression-changing 
aggression, and difficulty concentrating. On June 6, 2001, St. John’s wort 
ceased and these symptoms subsided. Three weeks later, St. John’s wort 
was restarted and the same symptoms appeared. St John’s wort was quitted 
and symptoms were relieved again. The reaction was considered medically 
significant
Table 6. 
Description of adverse status reports evaluated for the cause of natural product-drug interactions [15].
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may interact with synergistic or additives with CAM products, which can cause 
blood-thinning effects that may later cause excessive bleeding (Table 7) [16].
Herbs Dosage form/doses associated 
with safety concerns
Safety concerns
Panax ginseng Crude and standardized Ginseng 
root extract, high doses, combined 
preparation
It may hypoglycemic effect and can 
cause hypertension, as well as may 
interact with anticoagulants
Ginkgo biloba Standardized Ginkgo extract 
(EGb 761, 80 mg/day), crude 
Ginkgo plant parts (5 ppm of toxic 
ginkgolic acid)
It may interact with anticoagulants and 
can cause a severe allergic reaction
Cinnamomum cassia 
(L.) J.Presl
Cinnamon extract It may have hypoglycemic effect and may 
cause worsen liver conditions
Zingiber officinale Dried root, liquid extract, doses 
>10 g/day
It may interact with anticoagulants
Allium sativum Fresh garlic, dried powder (>7 g/
day), higher doses than usual 
dietary intake
It may interact with anticoagulants, 
antihypertensive, anti-hyperlipidemic, 
and hydrochlorothiazide
Andrographis 
paniculata (Burm.f.) 
Nees
Andrographis paniculata 
extract (50 and 100 mg/kg/
day) for 14 days, standardized 
Andrographis extract
It may interact with hepatic metabolizing 
enzymes, anticoagulant, antiplatelet, 
anti-hyperglycemic, barbiturates
Momordica charantia L. Bitter melon tea, bitter melon 
extract administered intravenously 
and intraperitoneally, high-dose 
bitter melon seed
It may hypoglycemic effect and may 
interact with hypoglycemic agents, death 
in children
Punica granatum L. Pomegranate juice, pomegranate 
extract
It may possibly interact with 
anticoagulants
Angelica sinensis (Oliv.) 
Diels
Dong Quai extract (tablet), dose: 
565 mg (1–2 tab/day) for 4 weeks
It may increase the risk of bleeding, 
increase cancer risk, as well as 
may interact with anticoagulants, 
antiplatelet, estrogen (augments the 
effect of estrogen)
Medicago sativa L. Alfalfa seed products It may cause autoimmune diseases (SLE, 
multiple sclerosis, rheumatoid arthritis), 
photosensitivity, estrogen-like and 
hypoglycemic effects, and may interact 
with immunosuppressants, warfarin, 
oral contraceptives, estrogen conjugates, 
oral hypoglycemic agents, iron, vitamin
Trigonella foenum-
graecum L.
Fenugreek seeds, fenugreek seed 
powder (>5 g)
It may have a hypoglycemic and 
estrogen-like effects
Camellia sinensis Tea (high dose >600 mg/day or 
2.25–4.5 L/day)
It may cause liver problems, and may 
interact with nadolol (beta-blocker), 
diuretics
Morinda citrifolia L. Noni juice, dose >400 mL It may cause liver toxicity, and contains 
high potassium
Spirulina A product containing blue-green 
algae
It may increase the risk of bleeding, 
may interact with immunosuppressant, 
antiplatelet, anticoagulants, NSAIDs, 
other herbs that reduce blood clotting 
(e.g., ginseng, garlic, ginkgo)
Table 7. 
The herbs used by CKD patients and their safety concerns [16].
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9.5 Herb-drug interactions with menopause medication
Herbal remedies are popular among women to relieve menopausal symptoms 
such as hot flashes, energy loss, depression, joint pain, and insomnia. As recently 
reviewed, a variety of herbs used to treat menopausal symptoms can cause herb-
drug interactions (Table 8) [17].
10. Herb-micronutrient interactions
The ability of some foods to reduce or increase the absorption of various 
vitamins and minerals has been known for years. Almost half of the popula-
tion regularly uses some herbal products as a dietary supplement, along with 
the vitamin and mineral supplements. The use of these products has increased 
significantly over the past two decades, and a number of clinically relevant 
herbal drug interactions have been identified during this time. Therefore, it is 
likely that the mechanisms underlying many herb-drug interactions may also 
affect micronutrient absorption, distribution, metabolism, and excretion. Not 
taking these eccentricities into account can negatively affect the outcome and 
 interpretation of any advanced herb-micronutrient interaction studies [18] 
(Table 9).
Herbs HID
Cimicifuga racemosa Increase the activity of antihypertensive agents
Angelica sinensis Inhibit platelet aggregation and increase risk of bleeding if co-medicated with 
anticoagulants
Oenothera biennis L. Potentially interacts with anti-inflammatory drugs, corticosteroids, beta-blockers, 
antipsychotics and anticoagulants
Trifolium pratense L. Increase the activity of CYP3A4 and alters the metabolism of drugs
Humulus lupulus L. Interact with CNS depressants, antipsychotics, hormones and CYP-metabolized 
drugs
Table 8. 
Herb-drug interactions with herbs for menopause.
Phytochemicals Micronutrient 
affected
Effect and interaction mechanisms
Plant polyphenols (PPs) (tea 
catechins, phloretin, quercetin)
Iron PPs reduce absorption through 
complexation
Folate, 
ascorbate
PPs reduce absorption through uptake 
transporter inhibition
Silymarins Iron They reduce absorption through 
complexation
Phytic acid Calcium, iron, 
zinc
It reduces absorption through complexation
Hyperforin (St. John’s wort) Vitamin D3 It enhances plasma clearance through 
induction of CYP3A4 metabolism
Table 9. 
Herb-micronutrient interactions and their mechanisms.
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11. Databases setup for plants/dietary supplements
The Integrative Medicine Service at Memorial Sloan Kettering Cancer Center 
has developed About Herbs (www.aboutherbs.com), which provides research 
information, including alleged uses, side effects, and herb-drug interactions for 
about 284 dietary supplements. Using Google Analytics, they have detected that 
more than 26,317,000 hits have been recorded since November 2002. According to 
these data, top 10 plant and/or dietary supplements in 2018 were chaga mushrooms, 
turmeric, ashwagandha, reishi mushroom, graviola, Active Hexose-Correlated 
Compound, boswellia, dandelion, green tea, and Coriolus versicolor. In Table 10, 
based on the literature researches in PubMed, their scientific and common names, 
plant-drug interactions and their appropriate use in the oncology environment are 
discussed. In the past 16 years, evidence of the use of these supplements is based on 
limited studies and mostly preclinical findings. It is important to inform healthcare 
professionals about popular dietary supplements so that patients can be informed to 
make decisions that maximize benefits and minimize risks [19] Hereby, important 
herb-drug interactions have been compiled in Table 11.
Common name Scientific name of 
the plants/dietary 
supplements
Key interaction and 
concerns
Avoid in
Chaga Inonotus obliquus (Ach. 
ex Pers.) Pilát
High in oxalates
Anticoagulants
Anti-platelets
Antihyperglycemic agents
Renal disease
Diabetic patients on 
treatment (acarbose)
Turmeric Curcuma longa High in oxalates
CYP2C9 enzyme
Renal disease
Ashwagandha Withania somnifera (L.) 
Dunal
Increase testosterone levels 
in men
Prostate cancer
Reishi 
mushroom
Ganoderma lucidum 
(Curtis) P.Karst.
Anticoagulants
Anti-platelets
Radiation therapy
Graviola Annona muricate L. Antihyperglycemic agents Diabetic patients on 
treatment
AHCC Active Hexose-
Correlated Compound
CYP2D6 enzyme inducer Breast cancer patients 
on doxorubicin, zofran, 
and aromatase inhibitor 
(letrozole)
Boswellia Boswellia serrata Roxb. 
ex Colebr.
Unknown Contact dermatitis
Dandelion Taraxacum mongolicum 
Hand.-Mazz., T. 
officinale (L.) Weber ex 
F.H.Wigg
CYP1A2 enzyme
Diuretic
Antihyperglycemic agents
Estrogenic activity
Hormone-sensitive 
breast cancer
Green tea Camellia sinensis High doses or taken on an 
empty stomach can cause 
liver toxicity Bortezomib
Elevated liver function 
tests
Turkey tail 
mushroom
Trametes versicolor (L.) 
Lloyd
Unknown Patients on 
immunosuppressants  
(in theory)
Table 10. 
Top 10 monographs accessed from the “about herbs” database in 2018.
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Plants Effect and usage Drugs Interactions
Allium sativum Antihypertensive, antithrombotic, 
fibrinolytic, antimicrobial, antidiabetic and 
lipid-lowering properties [20]
Anticoagulant May lead to increased anticoagulation effect of warfarin 
and may increase the risk of bleeding [21–23]
Antiretroviral (saquinavir) May decrease the plasma level of protease inhibitor 
saquinavir [24, 25]
Antidiabetic (metformin, chlorpropamide) May occur greater reduction in blood glucose level  
[26, 27]
Paracetamol (acetaminophen) May change some pharmacokinetic variables of 
paracetamol [28]
Aloe vera L. Laxative antidiabetic [20] Corticosteroids and potassium-depleting diuretics Laxative and potassium lowering effect may result in 
hypokalemia [29, 30]
Cardiac glycosides and antiarrhythmic drugs May enhance the hypokalemia-related arrhythmia  
[29, 30]
Antidiabetics Because of the glucose-lowering effects, diabetic patients 
should be careful when combining with an antidiabetic 
agent [31]
Cassia senna L. Laxative [20] Corticosteroids and potassium-depleting diuretics May lead to hypokalemia, since senna can cause 
excessive water and potassium loss, theoretically [20]
Digitalis glycosides Risk of digitalis toxicity due to hypokalemic effect of 
senna, theoretically [20]
Echinacea purpurea (L.) 
Moench.
As immunostimulant and in treatment of 
upper respiratory tract infections [20]
Anabolic steroids, amiodarone (antiaritmic), methotrexate 
(chemotherapy agent-immunosuppressant), ketoconazole 
(antifungal), and acetaminophen
The risk of hepatoxicity by concomitant usage of 
potentially hepatoxic Echinacea [32, 33]
Immunosuppressants Might decrease the effects of immunosuppressants, 
theoretically [34]
Midazolam (benzodiazepine) May increase oral bioavailability of midazolam or [20]
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Plants Effect and usage Drugs Interactions
Ginkgo biloba To improve cognitive functions, 
cerebrovascular disorders and vertigo [20]
Phenobarbital Reduces the therapeutic potency of phenobarbital [35]
Ibuprofen (NSAID) May cause fatal intracerebral bleeding [36]
Anticoagulant (warfarin) and antiplatelet (aspirin) drugs Possible additive inhibition on platelet aggregation [37, 38]
Antidepressant (trazodone) Ginkgo flavonoids increase the production of 
1-(m-chlorophenyl) piperazine (mCPP), an active 
metabolite of trazodone. Flavonoids and mCPP may 
induce the enhancement of GABAergic activity [34]
Thiazide diuretic (not specified in the original paper) Further increase in blood pressure [39]
Nicardipine (a calcium channel blocker) Decreasing the hypotensive activity of drugs [40]
Nifedipine, diltiazem (calcium channel blockers) and 
talinolol (β-blocker)
Possible increased antihypertensive activity resulting 
from high bioavailability [41–44]
Cyclosporine Decreased bioavailability of drug [45]
Midazolam (benzodiazepine) Decreased bioavailability of drug [46]
Propranolol (β-blocker) Decreased the plasma concentrations of propranolol [47]
Theophylline Less efficacy with Ginkgo [48]
Omeprazole (proton pump inhibitor) May induce the metabolism, and reduce the effect of 
omeprazole [49]
Tolbutamide (an antidiabetic drug) May increase or decrease the hypoglycemic effect of 
tolbutamide [50]
Amikacin (aminoglycoside) Amikacin ototoxicity may enhance [51]
Glycyrrhiza glabra Expectorant, antispasmodic and anti-
inflammatory properties and in treatment 
of peptic and duodenal ulcers [20]
Prednisolone (corticosteroid) Glycyrrhizin increases the plasma concentrations and 
potentiates pharmacological effects of prednisolone [52, 53]
Hydrocortisone (corticosteroid) Glycyrrhetinic acid potentiates the activity the topical 
cutaneous vasoconstrictor effect [54]
Dexamethasone (corticosteroid) Dexamethasone induces the mineralocorticoid effects of 
glycyrrhizin [55]
Antihypertensives Mineralocorticoid effects (sodium and water retention 
and hypokalemia) of plant reduce the efficacy of the 
drugs that use to lower blood pressure. Hypokalemic 
effect of the plant may increase the effect of the loop and 
thiazide diuretics [20]
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Plants Effect and usage Drugs Interactions
Hypericum perforatum To treat depression, seasonal affective 
disorder, anxiety and insomnia, especially 
related to menopause [20]
Gliclazide (an antidiabetic drug) Increases the apparent clearance of gliclazide [56]
Carbamazepine, phenytoin and phenobarbital 
(antiepileptics)
Clinically significant interaction is unlikely, but 
Hypericum should be used carefully with these 
antiepileptic drugs [20]
Alprazolam, midazolam, triazolam and quazepam 
(benzodiazepines)
Since the main compound hyperforin induces the 
enzyme CYP3A4, bioavailability may decrease [20, 57]
Indinavir (protease inhibitor)
Nevirapine (nonnucleoside reverse transcriptase)
May decrease the antiretroviral drugs and may lead to 
development of drug resistance [58, 59]
Cyclosporine, tacrolimus, (Immunosuppressants) May decrease the blood levels and may lead the acute 
organ rejection in transplant patients [60–62]
Warfarin and phenprocoumon (anticoagulants) May cause a moderate reduction in the anticoagulant 
effects of the drugs [20]
Simvastatin and atorvastatin (antihyperlipidemic agents) May observe the increasing serum level of total 
cholesterol [63, 64]
Nifedipine, verapamil (calcium channel blockers) and 
talinolol (a β-adrenoceptor blocker)
May decrease the bioavailability of drugs [65]
Oral contraceptives Associated with increased metabolism of ethinyl 
estradiol, norethindrone, and ketodesogestrel, and may 
cause bleeding and unwanted pregnancy [66–69]
Carbamazepine (antiepileptic) Should be considered a mild interaction between 
carbamazepine and Hypericum
Sertraline, nefazodone (selective serotonin reuptake 
inhibitors)
May be occurred the symptoms of central serotonergic 
syndrome [70]
Linum usitatissimum L. Demulcent for bronchitis and coughs, and 
topically used for burns [20]
Anticoagulant or antiplatelet drugs In the view of the thought that omega-3 fatty acids such 
as linolenic acid have antiplatelet effects, should be 
concerned about the possibility of prolonged bleeding [20]
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Plants Effect and usage Drugs Interactions
Panax ginseng Adaptogenic [20] Phenelzine (MAO inhibitor) Additive nervous system effect of drug such as headache, 
tremor, sleeplessness and mania [34]
Warfarin (anticoagulant) INR may decrease by concomitant usage [71]
Warfarin, heparin, aspirin, and NSAIDs There is no clear data, but due to the antiplatelet 
components in P. ginseng, it should be avoided 
concomitant using [32]
Caffeine Possible additive stimulant effects [20]
Piper methysticum Anxiolytic, sedative, aphrodisiac Barbiturates and benzodiazepines Might potentiate the effects of central nervous system 
depressants [72]
Alprazolam (benzodiazepine) Risk of coma due to possible additive effect on GABA 
receptor [72]
Levodopa May reduce the efficacy due to possible dopaminergic 
antagonism [73]
Acetaminophen May enhance the risk of hepatotoxicity [33]
Valeriana officinalis Used for stress and insomnia as sedative and 
anxiolytic [20]
Barbiturates Excessive sedation. The active component valerenic 
acid seems to likely to have the additive effect to 
phenobarbital [74]
Other central nervous system depressants such as 
benzodiazepines and opioids
Possible additive sedative effects [20]
Caffeine Possible reverse effect to the sedative effect of Valerian 
[20]
Zingiber officinale To reduce nausea and emesis induced 
by pregnancy, chemotherapy, and 
postoperative ileus [75]
NSAIDs May reduce the platelet aggregation and enhance the 
bleeding tendency [33]
Nifedipine May potentiate the antiplatelet effects [76]
Metronidazole May increase the bioavailability [77]
Glibenclamide (antidiabetic) May reduce the blood glucose level [26]
Table 11. 
Some herb-drug interactions.
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12. Criteria for risk assessment of herbal products
There have been an increasing number of herbal products as food ingredients or 
supplements, which are a commercially important part of the health food market. 
Herbal products can range from whole foods (e.g., cranberry against urinary 
infections) to pharmaceutical-like preparations in unit dose form, such as tablets, 
capsules, or drops, and are thought to provide additional benefits beyond basic 
nutrition. The regulatory position on food supplements is uncertain (food or medi-
cine?), and there is concern about the safety assurance of these products. Several 
cases of poisoning have been reported with herbal products. In some cases, these 
were caused by contamination with other plant species, but this is not always the 
case. In addition, toxic components (e.g., pyrrolizidine alkaloids) are accumulated 
at different concentrations in different parts of the source plant, and climatic and 
agronomic differences lead to great variability in the composition [78].
Therefore, it is not possible to provide a simple checklist of suitable tests to 
ensure the safety of herbal products. International guidelines are available for the 
safety assessment of herbal product and should be designed to cover all life stages to 
ensure a lifelong intake that can be consumed without significant health risk [78].
Information relating to herbal product identification, characterization, and 
standardization:
A. Botanical source: identity to family (geographic origin), genus, and species of 
source plant (with authority), and, if relevant, variety and chemotype; com-
mon names as well as part(s) of plant used. Evidence from previous human 
exposure through food or other sources (ethnobotanical and folk medicine 
studies).
B. Growing conditions: wild or cultivated plant (Good Agricultural Practice—GAP), 
site and time of harvest; stage of growth at harvest, post-harvest treatment 
(drying, fermentation, etc.), storage conditions, phytosanitary measures pre- and 
postharvest (including use of and limits for pesticides) are very important.
C. Raw material (fresh or dried plant materials): specifications according to 
standard reference (e.g., herbal Pharmacopoeias), identity tests (macroscopic, 
microscopic, FT-IR, TLC, GC, HPLC, etc.), quantitative tests (especially 
constituents related for efficacy and/or toxicity).
D. Process applied to starting material: preparation steps (e.g., separation, extrac-
tion processes, solvents), methods used, handling specific precautions; e.g., 
light/temperature sensitivity, oxidation, etc.
E. Botanical preparation: standardization criteria (markers: active constituents, 
other related components; plant extract ratio), specifications: levels and range 
for markers, physico-chemical properties of relevant components; stability, 
purity criteria by chain control or analysis; microbiological, mycotoxins, 
pesticides, and environmental contaminants. Nature and level of excipients; 
formulation methodology, storage conditions should have been specified.
F. End product: formulated product.
G. Specification of the product.
H. Extent of use and estimated intake (posology and method of administration).
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I. Bioavailability of active principles.
J. Toxicological assessment.
K. Preclinical and clinical studies. Clinical data including variability of response, 
adverse effects reports, and contraindications [78].
13. Possible ways to reduce the toxic effects of herbal products
Natural products/compounds are unique remedies, but as Paracelsus (1493–
1541) stated that all substances are poison and this is just the correct dose that 
makes them medicine. There are some rules in the literature that can be summa-
rized as follows:
a. If the herbal remedy is not prescribed by a registered physician, it should be 
considered unsafe.
b. The label and expiration date of the herbal products should be checked for the 
seal of the regulatory authority.
c. If the herbal medicine is consumed with allopathic medicines, the doctor 
should be informed.
d. Herbal products should not be used with drugs possessing narrow therapeutic 
index such as cyclosporin, digoxin, theophylline, and warfarin.
e. Herbal products containing heavy metals such as arsenic, lead, and mercury 
should not be used.
f. Pregnant or breastfeeding mothers should be careful when using herbal rem-
edies such as black cohosh, chamomile, sage, Dong Quai root, feverfew, ginger, 
kava kava, St. John’s wort, etc.
g. Excessive consumption of herbal/herbal medicine/natural products should be 
avoided and dosing instructions should be followed [3].
14. Conclusion
Herbal and traditional medicines are preferred as primary health care by three 
quarters of the world’s population. Therefore, it is crucial in drug research to 
investigate the effectiveness and adverse effects of herbal medicine, to identify the 
active compounds in medicinal plants and to detect contamination from poisonous 
plants or herbal mixtures. In 2013, the World Health Organization (WHO) pub-
lished the WHO traditional medicine strategy (2014–2023). It aims to support the 
use of Traditional Medicine (TM) and/or Complementary and Alternative Medicine 
(CAM) to improve public health, including phytotherapy using of medicinal prod-
uct (MP) and/or herbal medicinal product (HMP) for medical practice. The plan 
aims to increase the safety, efficacy, and quality of TM and/or CAM by expanding 
its knowledge base and providing guidance on regulatory and quality assurance 
standards (WHO, 2013). In 2016, the National Complementary and Integrative 
Health Center (NCCIH) published a strategic plan to explore complementary 
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and integrative health science. This plan has been published to inform the pub-
lic, healthcare professionals, and health policy makers, with evidence-based 
information about the usefulness and safety of complementary and integrative 
health interventions and their role in health care development. The plan uses key 
research to facilitate understanding of the biological effects, mechanisms of action, 
effectiveness, and clinical effects of complementary health approaches. Both the 
WHO and NCCIH plans aim to improve TM and CAM knowledge, including 
phytotherapy. Therefore, understanding herb-drug interactions and the molecular 
mechanisms involved in these processes is a way to guarantee safe use of MP and/or 
HMP. In addition, this can help therapeutic planning and healthcare professionals to 
recommend the best treatment strategy to use.
In this review, some critical issues are also discussed. The botanical identifica-
tion and labeling of the plant material are important for preventing undesirable 
health problems. The changes in the scientific definitions of the plants in traditional 
medicine in time can cause unwanted or toxicologic effects by the usage of the 
wrong plant. The contamination of the plants with the environmental contami-
nants (microorganisms, fungal toxins such as aflatoxins, pesticides, and heavy 
metals), inappropriate preparation process, and interaction of traditional herbs 
by concomitant or consecutive usage also endanger the safety of herbal medicine 
for human health. What makes herbal medicine research valuable is that it has the 
chance to research harmful and toxic plants for developing pharmacologically and 
therapeutically worth remedies, and to develop medicinal plant combinations as 
safe and efficient herbal medicines. Standardization and strict control mechanisms 
are essential to maintain the high quality of herbal products and to prevent from the 
contaminations for the safety of patients [17].
The following guidelines can be suggested to minimalize the risk of herbal uses:
1. Should not be used in case of pregnancy or a possibility of pregnancy and to 
babies.
2. Should not be used when breast-feeding.
3. Should not be used as daily and in large amounts.
4. Should be bought from the pharmacies and only in case the plant names are 
stated on the packages and sealed by the Ministry of Health.
Do not believe it is useless if it is natural or it is harmless if it is natural [79].
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